Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
Subscribe To Our Newsletter & Stay Updated